- €2.20bn
- €2.16bn
- €1.11bn
Brief: Almirall Announces Positive, Top-Line Results From Phase 3 Adorable-1 Trial
Spain's Almirall in talks with 'dozens' of firms to license China assets, CEO says
Spanish stocks - Factors to watch on Feb 23
Spain's Almirall 2025 sales jump 12.4% on European dermatology business strength
Brief: Almirall FY Net Income EUR 46.2 Million
Brief: Almirall Sees FY Net Sales Growth Between 9% And 12% Vs 2025
Spanish stocks - Factors to watch on Jan 29
Brief: Almirall Gets Approval For Acne Treatment Seysara In China
Brief: Almirall Gets 16.8 Mln Euros From CDTI For Dermatology Development
BNP sees slowdown in Spanish mid-caps in 2026 after outperforming year
Spanish stocks - Factors to watch on Jan 20
Spanish stocks - Factors to watch on Jan 15
Brief: Almirall To Start Phase III Study On Lebrikizumab For Nummular Eczema
Spanish stocks - Factors to watch on Jan 12
Brief: Almirall Says Lebrikizumab New Phase III Study In Nummular Eczema To Start Enrolling Patients In Q2 2026
Europe Research Roundup: BNP Paribas, Swedbank, Volkswagen
Spanish stocks - Factors to watch on Jan 9
Spanish stocks - Factors to watch on Dec 18
Brief: Almirall Completes 250 Mln Euro Senior Notes Issuance At 3.75% Interest